NATHBIOGEN — Nath Bio-Genes (I) Income Statement
0.000.00%
Last trade - 00:00
- IN₹4.69bn
- IN₹3.39bn
- IN₹3.33bn
- 50
- 73
- 64
- 72
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,799 | 3,076 | 2,784 | 3,014 | 3,326 |
Cost of Revenue | |||||
Gross Profit | 1,616 | 1,815 | 1,632 | 1,958 | 1,991 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,267 | 2,435 | 3,330 | 2,556 | 2,854 |
Operating Profit | 532 | 640 | -546 | 457 | 472 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 485 | 568 | -634 | 362 | 381 |
Provision for Income Taxes | |||||
Net Income After Taxes | 505 | 557 | -673 | 350 | 362 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 505 | 557 | -673 | 350 | 396 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 505 | 557 | -673 | 350 | 362 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 26.5 | 29.3 | -5.07 | 18.4 | 19.3 |
Dividends per Share |